Chemical formula: C₁₈₇H₂₉₁N₄₅O₅₉ Molecular mass: 4,113.641 g/mol
Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BJ06 | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| OZEMPIC Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| WEGOVY Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RYBELSUS Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Semaglutide is an active ingredient of these brands:
Australia (AU)Cyprus (CY)Ecuador (EC)Hong Kong (HK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
